• PolyNovo requests trading halt for announcement on results of clinical trial
• Halt to remain in place until 16th September 2025 or release of announcement
• Company not aware of any reason why trading halt should not be granted

PolyNovo Ltd has requested an immediate trading halt in its securities (ASX Code: PNV) pending the release of an announcement. The trading halt has been requested in respect of a poster made public on the results of a chronic wound investigator initiated randomised controlled clinical trial comparing the use of NovoSorb BTM combined with negative pressure wound therapy (NPWT) to the clinical standard of care (NWPT alone) in subjects with neuroischemic diabetic wounds. Unless otherwise requested by the Company, PNV has requested the trading halt to remain in place until the release of an announcement or the opening of the market on Tuesday 16th September 2025. The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.